Dr. Reddys Laboratories Ltd.
BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1245.50
-24.30 (-1.91%) Dr. Reddy’s gets USFDA observations for Srikakulam facility
Date: 17-06-2017US Food and Drug Administration (USFDA) has completed audit of Dr. Reddy’s Laboratories’ Formulations Srikakulam Plant (SEZ) Unit I, Andhra Pradesh, on June 16, 2017. The pharma major has been issued a Form 483 with one observation, which it is addressing.
Recently, USFDA had completed audit of the company’s Formulations Srikakulum Plant (SEZ) Unit II, Andhra Pradesh on May 25, 2017 with zero observations.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.